Parallel Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-259
| Closed | -$5.58K | – | 3839 |
|
|
2025
Q4 | $5.58K | Buy |
259
+23
| +10% | +$447 | ﹤0.01% | 2810 |
|
|
2025
Q3 | $3.6K | Buy |
236
+55
| +30% | +$716 | ﹤0.01% | 2903 |
|
|
2025
Q2 | $1.6K | Buy |
+181
| New | +$1.59K | ﹤0.01% | 3094 |
|
|
2025
Q1 | – | Sell |
-128
| Closed | -$1.34K | – | 3519 |
|
|
2024
Q4 | $1.34K | Buy |
128
+86
| +205% | +$1.04K | ﹤0.01% | 3059 |
|
|
2024
Q3 | $551 | Hold |
42
| – | – | ﹤0.01% | 3166 |
|
|
2024
Q2 | $591 | Hold |
42
| – | – | ﹤0.01% | 3070 |
|
|
2024
Q1 | $709 | Hold |
42
| – | – | ﹤0.01% | 2995 |
|
|
2023
Q4 | $593 | Hold |
42
| – | – | ﹤0.01% | 3033 |
|
|
2023
Q3 | $433 | Hold |
42
| – | – | ﹤0.01% | 3132 |
|
|
2023
Q2 | $692 | Hold |
42
| – | – | ﹤0.01% | 3027 |
|
|
2023
Q1 | $385 | Buy |
+42
| New | +$345 | ﹤0.01% | 3178 |
|
|
2021
Q3 | – | Sell |
-128
| Closed | -$1K | – | 3069 |
|
|
2021
Q2 | $1K | Buy |
+128
| New | +$1.02K | ﹤0.01% | 2688 |
|
|
2018
Q2 | – | Sell |
-697
| Closed | -$5K | – | 2087 |
|
|
2018
Q1 | $5K | Sell |
697
-264
| -27% | -$2.32K | ﹤0.01% | 1530 |
|
|
2017
Q4 | $8K | Buy |
+961
| New | +$9.01K | ﹤0.01% | 1367 |
|
Other funds holding AVDL
Parallel Advisors's AVDL Position: Q1 2026 in Review
Parallel Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 259 shares — an estimated $5.58K sold.
Parallel Advisors first reported a position in AVDL in Q4 2017 and held it in 14 quarters. The position peaked at $8K in Q4 2017. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Parallel Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Parallel Advisors sold 259 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.58K.
- Parallel Advisors first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 14 quarters.
- Parallel Advisors's Avadel Pharmaceuticals position peaked at $8K in Q4 2017.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.